John Tsai, Head of Global Drug Development and Chief Medical Officer, describes how he balances innovation and patient needs.

Jay Bradner discusses his vision for an open framework of scientific discovery at Novartis.

The race is on to find a new treatment before resistance to today’s drugs becomes widespread.

Spinal muscular atrophy (SMA) is the most common genetic casue of infant and toddler death. NIBR scientists are trying to make a back up gene take up the slack.

Novartis researchers are partnering with advocacy groups to understand the stigma and challenges facing patients with obesity.

An investigational treatment for an uncommon immunodeficiency disease races into clinical studies.

Researchers focus on reversing the scarring that’s common to liver diseases.